Medincell Publishes Its Consolidated Half-year Financial Results [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
Key highlights Sales growth of UZEDY ® in the United States €2.8 million in royalties invoiced by Medincell over the period Upward revision of Teva's 2024 net sales forecast from $80 million to $100 million U.S. net sales year-to-date 2024: $75 million U.S. net sales in Q3 2024: $35 million Olanzapine LAI (mdc-TJK): positive results from the pivotal phase 3 trial Positive efficacy results announced in May 2024 No cases of post-injection delirium/sedation syndrome (PDSS) observed after 100% of injections planned for regulatory submission Submission of the US marketing application by Teva expected in the first half of 2025 Christophe Douat, CEO of Medincell, said: "Eighteen months after its launch, UZEDY is experiencing strong success in the United States, with sales expected to reach $100 million in 2024, its first full year of commercialization. Phase 3 of olanzapine has concluded with positive results, paving the way for a market authorization submission in the c
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025GlobeNewswire
- My Top 10 Portfolio Holdings for 2025 [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $25.00 to $28.00. They now have an "overweight" rating on the stock.MarketBeat
- Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 11/6/24 - Beat
TEVA
Sec Filings
- 12/20/24 - Form 144
- 12/4/24 - Form 4
- 12/4/24 - Form 3
- TEVA's page on the SEC website